Bayer and Cedilla Therapeutics announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers. Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers. Cedilla's small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition.

This specific method of action that Cedilla has discovered allows for precise targeting in a selected patient population with high unmet need and has the potential to enhance safety and efficacy in comparison to standard of care. Under the terms of the agreement, Bayer will receive full rights on the development and commercialization of Cedilla's CyclinE1/CD K2 complex inhibitors. Cedilla will receive an upfront payment and potential development and commercial-based milestone payments.

Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer. Financial details have not been disclosed.